key: cord-0828127-9vavks3a authors: Klein, Elizabeth J.; Hardesty, Anna; Vieira, Kendra; Farmakiotis, Dimitrios title: Use of anti‐spike monoclonal antibodies in kidney transplant recipients with COVID‐19: Efficacy, ethnic and racial disparities date: 2021-09-30 journal: Am J Transplant DOI: 10.1111/ajt.16843 sha: b8679223535033631984d35949096e027a444343 doc_id: 828127 cord_uid: 9vavks3a Organ transplant recipients may not mount an adequate immune response to COVID‐19 infection and therefore may benefit greatly from passive immunization with anti‐spike monoclonal antibodies (mAbs), which have been shown to decrease hospitalization rates in the general outpatient population. We evaluated the efficacy of mAb therapy in decreasing hospitalizations or emergency room (ER) visits among kidney transplant recipients (KTR) with COVID‐19. We identified KTR with COVID‐19 between March 1, 2020 and April 30, 2021. Patients were excluded if they had multi‐organ transplant or hospital‐acquired COVID‐19. We studied 95 KTR; 20 received mAb. mAb administration was associated with a significant decrease in hospitalizations or ER visits (15% vs. 76%, p < 0.001). This association remained significant after adjustment for potential confounders, and analysis of mAb administration as a time‐dependent variable, with day of symptom onset as day 1 (adjusted HR 0.216, p = 0.04). Black or Hispanic patients were less likely to receive mAb and more likely to be admitted to the hospital or visit the ER. In our KTR population, mAb therapy for COVID‐19 may have helped decrease hospitalizations and ER visits. Healthcare inequities, including access to investigational treatments, have been exacerbated by the COVID‐19 pandemic. Antiviral mAbs are a promising therapeutic modality, especially for immunocompromised patients. antibody (mAb) therapy, but this hypothesis warrants further investigation. Bamlanivimab and casirivimab/imdevimab were granted emergency use authorization (EUA) status for the treatment of mild to moderate COVID-19 in November 2020. Bamlanivimab/etesevimab received EUA status for the same indication in February 2021. 6 These mAbs have been shown to decrease the rates of hospitalization in the general outpatient population. [7] [8] [9] [10] Small case series of OTR with COVID-19 have also reported good efficacy and tolerability with 11 or without [12] [13] [14] [15] [16] [17] comparator groups. In this study, we retrospectively evaluated the efficacy and tolerability of anti-spike mAb therapy in our cohort of kidney transplant recipients (KTR) with COVID-19, and compared clinical outcomes between KTR who received mAbs and those who did not, adjusting for potential confounders. We identified KTR diagnosed with COVID-19 at Brown Universityaffiliated hospitals between March 1, 2020 and April 30, 2021. Details of our transplant population and protocols were previously described. 18 OTR diagnosed with COVID-19 after the EUA for bamlanivimab (November 9, 2020) were eligible for anti-spike mAb administration if they: (1) were not hospitalized due to COVID-19, (2) did not require oxygen therapy (or increased oxygen flow rate if already receiving oxygen for a different indication) due to COVID-19, and (3) had symptoms for <10 days, given that mAbs are most effective when given early in the course of COVID-19. The primary endpoint was hospitalization or emergency room (ER) visit after COVID-19 symptom onset. Secondary endpoints were mechanical (invasive or noninvasive) ventilation and all-cause in-hospital mortality or discharge to hospice. The study was approved by the Lifespan Institutional Review Board. Patients were excluded if they contracted COVID-19 while in the hospital, thereby conflicting with the primary endpoint. We also excluded multi-organ transplant recipients to achieve a homogeneous population-such patients often have more comorbidities and require higher levels of immunosuppression. We performed sensitivity analyses for the primary endpoint after exclusion of patients who had COVID-19 when mAbs were not available and those who were admitted at the time of first evaluation, due to hypoxia or other reasons <10 days of symptom onset. Data are presented as median (interquartile range [IQR]) for continuous variables and number (%) for categorical variables, which were compared with the Mann-Whitney U test and Fisher's exact test, respectively. To adjust for possible confounders and "immortal bias," 19, 20 we performed univariate and multivariate Cox regression analyses with the day of symptom onset as baseline (day 1) and mAb administration as time-dependent variable. Factors with a p-value of <.2 on univariate analyses were entered in the multivariate models. Immortal bias occurs when cohort members cannot experience an outcome until the time of cohort entry. In our study, patients could not have the primary outcome (hospitalization or ER visit) until the time of mAb administration (up to 10 days). This can lead to a spurious benefit from mAb administration, if mAb administration is analyzed as a time-fixed variable. Therefore, we analyzed mAb administration as a time-dependent variable, that is, patients who received mAb were considered "controls" up to the time point of mAb administration. 19, 20 To further adjust for residual confounding, we estimated a propensity score (PS) as the logistic regression-based probability for mAb administration, including age, sex, race, ethnicity, BMI, time from transplantation, and comorbidities. We built Cox regression models using the PS as covariate, either alone or added to other significant covariates ("double robust" model). We used 1:1 nearest neighbor matching without replacement and caliper distance of 0.2x the pooled standard deviation of the PS. Patients who did not have a match were excluded, and a matched-pair analysis was conducted. All analyses were performed with SPSS statistical software, version 24.0 (IBM Corporation). Statistical significance was set at a twotailed p-value of .05. We studied 95 KTR. Demographic and clinical characteristics are summarized in Table 1 . Twenty patients received mAb as outpatients-15 received bamlanivimab, 1 received bamlanivimab/etesevimab, and 3 received casirivimab/imdevimab. One patient received anti-spike mAb at an outside center with no additional information available to us other than the date of administration. All patients tolerated the infusion well; three patients experienced worse fever and fatigue the night of mAb infusion. One patient reported these symptoms persisted and was admitted to the hospital, where he was found to be afebrile, without significant symptoms or signs, and was discharged after 2 days. Of the 75 patients who did not receive mAb, 27 had COVID-19 before mAbs became available under EUA. Of the remaining 48 patients: 19 were admitted to the hospital for COVID-19 due to hypoxia or other reasons <10 days of symptom onset, 6 refused mAb, 6 had symptoms for >10 days, and for 17 patients the reasons were unclear without documented offer of mAb treatment. More patients in the group who did not receive mAb had chronic kidney disease (CKD). Patients who received mAb therapy were more frequently men and had higher body mass index (BMI), although these differences did not reach statistical significance at the 0.05 level (Table 1) . Black or Hispanic patients were less likely to receive mAbs, constituting 5% and 15% of the group who received mAb therapy, as opposed to 19% and 33% of those who did not, respectively. Being Black or Hispanic was significantly associated with lower likelihood of mAb administration ( (Table S1 ). The reasons why KTR did not receive mAbs by race and ethnicity are summarized in Table S2 . Six of 11 (54.5%) Black and seven of 12 (58.5%) Hispanic KTR were not given mAbs when they were available, because they had symptoms >10 days or required hospital admission, compared to 12 of 25 (48%) non-Black, non-Hispanic KTR. There were no significant differences in baseline immunosuppression between KTR who received mAbs and those who did not. Among patients on an antimetabolite, more patients who did not receive mAbs eventually had it discontinued or the dose decreased (43/60 [72%]), compared to those who did (8/18 [44%] , p = 0.047). On univariate analysis, mAb administration was associated with a marked decrease in hospitalizations or ER visits (3/20 [15%] vs. TA B L E 1 Comparison of baseline characteristics and outcomes between KTR with COVID-19 who received anti-spike monoclonal antibody treatment as outpatients and those who did not Figure S1 ). None of the patients who received mAbs died or required mechanical ventilation. Of the patients who did not receive mAb, 13 (17%) required mechanical ventilation (p = .06 compared to KTR treated with mAbs), seven (9%) died, and one was discharged to hospice (11% mortality or discharge to hospice among patients who were not treated as outpatients with mAbs, 8% overall; Table 1 ). Regarding variants of interest (VOI) or concern (VOC), the weekly frequencies of VOI/VOC during the study period were recently reported in a large sample of specimens from Rhode Island (RI). 21 The most frequent VOI with the potential to be nonsusceptible to bamlanivimab during the study period was the Iota (New York origin) variant B.1.526, but not all isolates of this lineage are nonsusceptible to bamlanivimab. 22 The two next most frequent nonsusceptible VOI were the Epsilon vari- There is conflicting evidence regarding clinical outcomes 3,4 and appropriate immune response among OTR with COVID-19 compared to immunocompetent individuals, further confounded by the lack of an established threshold for protective immunity. 23 In our patient population, mAb therapy was well-tolerated and associated with less hospitalizations or ER visits in KTR with COVID-19. This association remained significant after adjustment for potential confounders. Our findings are in agreement with two randomized controlled trials 7, 9 and three retrospective studies. 8, 10, 11 However, efficacy in transplant recipients was not explicitly analyzed in the clinical trials 7,9 and one retrospective report. 10 Kumar et al. 8 To our knowledge, our study is one of the first to compare OTR who received anti-spike mAbs with those who did not, adjusting for demographics and comorbidities. Notably, among KTR treated with mAbs, in addition to significantly better clinical outcomes, we captured less frequent discontinuation or decrease in the dose of the antimetabolite (Table 1) . Therefore, another benefit of outpatient management of COVID-19 with mAbs in OTR may be less needed to adjust immunosuppression for severe disease, risking subsequent organ rejection. Importantly, our results highlight the health inequities exacerbated by the COVID-19 pandemic. Black race and Hispanic ethnicity were strongly associated with hospitalization or ER visit and these patients were the minority in the group receiving mAbs. The latter finding agrees with a recent large-scale report, which, nevertheless, included mostly White non-Hispanic patients. 24 It is possible that novel therapeutics for COVID-19 are less accessible to patients who identify as minorities. 25 To this end, we explored potential determinants of ethnic and racial disparities. Our Hispanic or Black KTR were not hesitant to consent to mAb treatment, as the numbers of Hispanic or Black patients who declined mAbs were extremely low, and the proportions numerically lower, compared to non-Black, non-Hispanic KTR (Table S2) . Black or Hispanic patients were closer to the infusion center, compared to non-Black, non-Hispanic KTR (Table S1 ); therefore, access to care probably did not play a major role either, although we did not assess means of transportation. Clearly, our Hispanic community was overrepresented earlier in the pandemic, when mAbs were not available (Tables S1 and S2 ). 26 The proportion of Hispanic, but not Black, KTR in our study decreased significantly over time. This was likely the result of a coordinated outreach to the Hispanic population of RI, 26 speaking to the power of community efforts and patient education. We noted a trend for more frequent comorbidities in Black patients (Table S1 ). Higher complexity favors the acceptance of investigational treatments. 24 For these reasons, and given the overall better outcomes in later stages of the pandemic, 28,29 residual confounding is possible. However, the two groups of KTR had similar baseline characteristics and the results remained significant after adjustment for potential confounders and immortal bias. 19, 20 Moreover, the benefit associated with mAb administration was significant after PSM, after exclusion of KTR from the pre-mAb EUA stage of the pandemic, and after exclusion of those who were not eligible for outpatient mAb administration because they required hospital admission due to hypoxia or other reasons. It should also be noted that none of the patients who received mAbs died or required mechanical ventilation. Therefore, despite study limitations, our conclusions are well-aligned with those of two randomized, double-blinded, placebo-controlled clinical trials, 7, 9 and two large retrospective studies with concurrent controls. 8, 10 In summary, we found a strong signal for less hospitalizations or ER visits in KTR who received anti-spike mAbs, compared to those who did not. Based on our results and those of multiple other studies, [11] [12] [13] [14] 16 The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Dimitrios Farmakiotis https://orcid.org/0000-0001-8489-108X Mortality in organ transplant recipients with Covid-19 compared to non-transplant or waitlisted patients: a meta-analysis Is COVID-19 infection more severe in kidney transplant recipients? COVID-19 outcomes among solid organ transplant recipients: a case-control study Immune responses to SARS-CoV-2 in solid organ transplant recipients Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19 Real-world experience of bamlanivimab for COVID-19: a case-control study REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19 Early monoclonal antibody administration can reduce both hospitalizations and mortality in high-risk outpatients with COVID-19 Anti-SARS-Cov-2 monoclonal antibodies in solid-organ-transplant patients Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: Early single-center experience Monoclonal antibodies for Covid-19 in patients with solid organ transplant recipients Bamlanivimab for Covid-19 in kidney Monoclonal antibody therapy for COVID-19 in solid organ transplant recipients Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients Casirivimab-imdevimab for treatment of COVID-19 in solid organ transplant recipients: an early experience Coronavirus disease 2019 in kidney transplant recipients: single-center experience and casecontrol study Handling timedependent variables: antibiotics and antibiotic resistance Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes SARS-CoV-2 variants in Rhode Island Update: FDA revokes emergency use authorization for monoclonal antibody bamlanivimab Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19 Call for action: racial disparities in clinical research Responding to COVID-19 in an uninsured hispanic/latino community: testing, education and telehealth at a free clinic in providence Department of Health and Human Services Pause in the distribution of bamlanivimab/etesevimab Platform trials-Beware the noncomparable control group Variation of mortality from SARS-CoV-2 infection in kidney